Responses of Unmyelinated Nerves to Axonal Transection and Neuronal Loss

2015 ◽  
pp. 166-173
Author(s):  
A. J. Aguayo ◽  
J. M. Peyronnard ◽  
J. B. Martin ◽  
G. M. Bray
Keyword(s):  
Neuronal Loss ◽  
Axonal Transection

Paricalcitol Accelerates BACE1 Lysosomal Degradation and Inhibits Calpain-1 Dependent Neuronal Loss in APP/PS1 Transgenic Mice

2019 ◽  
Author(s):  
Yong-Gang Fan ◽  
Tian Guo ◽  
Xiao-Ran Han ◽  
Jun-Lin Liu ◽  
Yu-Ting Cai ◽  
...  
Keyword(s):  
Transgenic Mice ◽  
Neuronal Loss ◽  
Lysosomal Degradation

Age-Related Mitochondrial Alterations without Neuronal Loss in the Hippocampus of a Transgenic Model of Alzheimer's Disease

2013 ◽  
Vol 10 (4) ◽  
pp. 390-405 ◽  
Author(s):  
Mar Cuadrado-Tejedor ◽  
Jesus Felipe Cabodevilla ◽  
Marta Zamarbide ◽  
Teresa Gomez-Isla ◽  
Rafael Franco ◽  
...  
Keyword(s):  
Neuronal Loss ◽  
Transgenic Model ◽  
Mitochondrial Alterations ◽  
Age Related

(±)-3,5-Bis(substitutedmethyl)pyrrolidines: Application to the Synthesis of Analogues of glycine-L-proline-L-glutamic Acid (GPE)

2018 ◽  
Vol 15 (2) ◽  
pp. 230-236 ◽  
Author(s):  
Joana Ferreira da Costa ◽  
Xerardo Garcia-Mera ◽  
David Silva Poceiro ◽  
Olga Caamano
Keyword(s):  
Therapeutic Strategy ◽  
Dimethyl Ester ◽  
Neuronal Loss ◽  
New Drugs ◽  
Ester Hydrochloride ◽  
1H And 13C Nmr ◽  
Survival Factor ◽  
Synthetic Strategy ◽  
Β Amyloid ◽  
Structural Simplicity

Backiground: Alzheimer's disease is a fatal, complex, neurodegenerative disease over 46 million people live with dementia in the world characterized by the presence of plaques containing β-amyloid and neuronal loss. The GPE acts as a survival factor against β-amyloid insult in brain and suggests a possible new therapeutic strategy for the treatment of Central Nervous System injuries and neurodegenerative disorders. The structural simplicity of GPE makes it a suitable lead molecule for the development of new drugs that to cross the blood-brain barrier. Objective: With these aims in mind, we embarked on a synthetic program focused on the modification of the Lproline residue of GPE in order to investigate its importance on the neuroprotective activities. Method: The general synthetic strategy involved the preparation of several modified proline residues, which were subsequently coupled to N-Boc-glycine-OH and glutamic dimethyl ester hydrochloride. Results: the mixture of compounds 11 was obtained in good yields (72%) under these conditions, and this was readily separated by column chromatography and the components were identified by 1H and 13C NMR spectral, as well as by its EI HRMS. Conclusion: Compound (±)-8 was coupled with L-glutamic dimethyl ester hydrochloride gave a mixture of dipeptides 9a and 9b in a satisfactory yield. The use of T3P as coupling agent of the mixture 10a and 10b with Boc-glycine provided a new analogue of GPE, tripeptide 11, obtained with an overall yield of 65% from (±)-1.

scholarly journals 421 - Mood disorders and its relationship with cognitive impairment and dementia

2020 ◽  
Vol 32 (S1) ◽  
pp. 137-137
Author(s):  
Sandra Torres ◽  
Andreia Lopes
Keyword(s):  
Cognitive Impairment ◽  
Mood Disorders ◽  
Neuronal Loss ◽  
Neurocognitive Impairment ◽  
Attention And Memory ◽  
Psychiatric Illnesses ◽  
Neurocognitive Functions ◽  
The Many ◽  
The One ◽  
Published Research

ABSTRACT:Mood disorders are common psychiatric illnesses that represent a major cause of disability worldwide. With life expectancy and the percentage of elderly people rising in many developed and undeveloped countries around the globe, cognitive impairment and dementia are gaining a societal importance. The relation between mood disorders and cognitive function is a twofold. On the one hand, cognitive deficits within mood disorders have been studied extensively, in which there seems to be a persistent neurocognitive impairment, both in acute phases and in interepisodic euthymic phases. Although results have not always been consistent, an overall pattern of specific impairments – in executive function, attention and memory - has become evident. On the other hand, recent research suggests that mood disorders, in general, may be risk factors for the development of mild cognitive impairment and dementia. In this sense, of the many models for the association of mood disorders and dementia, two are favored by several authors. One suggests that mood disorders are a risk factor for earlier clinical manifestation of dementia. The second sees mood disorders as the cause of dementing states, for instance through neuronal loss via dysregulation of the glucocorticoid cascade. In fact, there is suggestion that impairment of neuroplasticity may underlie the pathophysiology of mood disorders as such, and not only of neurocognitive impairment. In some patients, specific neurocognitive functions may be present before the onset of mood disorder and may constitute a trait factor or even an endophenotype. The aim of the present work is to, through a basic narrative review of published research on the main databases, summarize the main evidences of the association of mood disorders and dementia.

scholarly journals An autopsy-proven case of Corticobasal degeneration heralded by Pontine infarction

BMC Neurology ◽  
2021 ◽  
Vol 21 (1) ◽  
Author(s):  
Dallah Yoo ◽  
Sung-Hye Park ◽  
Sungwook Yu ◽  
Tae-Beom Ahn
Keyword(s):  
Neurodegenerative Disorders ◽  
Clinical Manifestations ◽  
Neuronal Loss ◽  
Corticobasal Degeneration ◽  
Executive Dysfunction ◽  
Lacunar Infarction ◽  
Cortical Atrophy ◽  
Dystonic Posturing ◽  
Proven Case ◽  
The Right

Abstract Background Neurodegenerative disorders are characterized by insidious progression with poorly-delineated long latent period. Antecedent clinical insult could rarely unmask latent neurodegenerative disorders. Here, we report an autopsy-proven case of corticobasal degeneration which was preceded by a lacunar infarction. Case presentation A 58-year-old man presented with acute ataxia associated with a lacunar infarction in the right paramedian pons. His ataxia persisted with additional progressive gait difficulty and left arm clumsiness. Six months later, a follow-up neurological examination showed asymmetrical bradykinesia, apraxia, dystonic posturing, postural instability, and mild ataxia of the left limbs. Cognitive examination revealed frontal executive dysfunction and visuospatial difficulties. Dopamine transporter imaging scan demonstrated bilateral reduced uptakes in mid-to-posterior putamen, more prominent on the right side. Levodopa-unresponsive parkinsonism, asymmetric limb dystonia, and ideomotor apraxia became more conspicuous, while limb ataxia gradually vanished. The patient became unable to walk without assistance after 1 year, and died 4 years after the symptom onset. Autopsy findings showed frontoparietal cortical atrophy, ballooned neurons, and phosphorylated tau-positive astrocytic plaques and neuropil threads with gliosis and neuronal loss, confirming the corticobasal degeneration. Conclusions The case illustrates that precedent clinical events such as stroke might tip a patient with subclinical CBS into overt clinical manifestations.

scholarly journals Mechanisms of Neurodegeneration in Various Forms of Parkinsonism—Similarities and Differences

Cells ◽  
2021 ◽  
Vol 10 (3) ◽  
pp. 656
Author(s):  
Dariusz Koziorowski ◽  
Monika Figura ◽  
Łukasz M. Milanowski ◽  
Stanisław Szlufik ◽  
Piotr Alster ◽  
...  
Keyword(s):  
Neurodegenerative Diseases ◽  
Tau Protein ◽  
Protein Gene ◽  
Clinical Presentation ◽  
Neuronal Loss ◽  
Corticobasal Degeneration ◽  
Inflammatory Factors ◽  
Parkinsonian Disorders ◽  
Genetic Features ◽  
The Brain

Parkinson's disease (PD), dementia with Lewy body (DLB), progressive supranuclear palsy (PSP), corticobasal degeneration (CBD) and multiple system atrophy (MSA) belong to a group of neurodegenerative diseases called parkinsonian syndromes. They share several clinical, neuropathological and genetic features. Neurodegenerative diseases are characterized by the progressive dysfunction of specific populations of neurons, determining clinical presentation. Neuronal loss is associated with extra- and intracellular accumulation of misfolded proteins. The parkinsonian diseases affect distinct areas of the brain. PD and MSA belong to a group of synucleinopathies that are characterized by the presence of fibrillary aggregates of α-synuclein protein in the cytoplasm of selected populations of neurons and glial cells. PSP is a tauopathy associated with the pathological aggregation of the microtubule associated tau protein. Although PD is common in the world's aging population and has been extensively studied, the exact mechanisms of the neurodegeneration are still not fully understood. Growing evidence indicates that parkinsonian disorders to some extent share a genetic background, with two key components identified so far: the microtubule associated tau protein gene (MAPT) and the α-synuclein gene (SNCA). The main pathways of parkinsonian neurodegeneration described in the literature are the protein and mitochondrial pathways. The factors that lead to neurodegeneration are primarily environmental toxins, inflammatory factors, oxidative stress and traumatic brain injury.

Sign in / Sign up

Export Citation Format

Share Document